Checkpoint Therapeutics I...

4.05
0.01 (0.25%)
At close: Apr 02, 2025, 3:59 PM
4.04
-0.25%
After-hours: Apr 02, 2025, 07:46 PM EDT
0.25%
Bid 4.01
Market Cap 336.41M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -1.42
PE Ratio (ttm) -2.85
Forward PE 10.7
Analyst Hold
Ask 4.08
Volume 753,963
Avg. Volume (20D) 2,433,456
Open 4.03
Previous Close 4.04
Day's Range 4.02 - 4.05
52-Week Range 1.38 - 4.50
Beta 1.42

About CKPT

Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-...

Industry Biotechnology
Sector Healthcare
IPO Date Dec 19, 2016
Employees 23
Stock Exchange NASDAQ
Ticker Symbol CKPT
Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for CKPT stock is "Hold." The 12-month stock price forecast is $4.1, which is an increase of 1.23% from the latest price.

Stock Forecasts
3 weeks ago
+61.13%
Checkpoint Therapeutics shares are trading higher ... Unlock content with Pro Subscription
9 months ago
+15.56%
Checkpoint Therapeutics shares are trading higher after the company announced it reached alignment with the FDA on its on its biologics license application resubmission strategy for cosibelimab.